Sanofi’s Tolebrutinib Advances MS Treatment

Sanofi (SNY) has released an update.

Sanofi’s tolebrutinib shows promise as the first potential treatment for non-relapsing secondary progressive multiple sclerosis (nrSPMS) by meeting its primary endpoint in the HERCULES phase 3 study, despite the GEMINI studies not meeting the primary endpoint for relapsing MS. Preliminary liver safety results are consistent with previous studies and detailed study findings will be presented at the ECTRIMS conference. Tolebrutinib’s ability to delay disability progression marks a significant advancement in addressing the unmet medical need in nrSPMS.

For further insights into SNY stock, check out TipRanks’ Stock Analysis page.